John H. Sampson

36.8k total citations · 10 hit papers
385 papers, 24.7k citations indexed

About

John H. Sampson is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, John H. Sampson has authored 385 papers receiving a total of 24.7k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Oncology, 166 papers in Genetics and 151 papers in Immunology. Recurrent topics in John H. Sampson's work include Glioma Diagnosis and Treatment (164 papers), Immunotherapy and Immune Responses (118 papers) and CAR-T cell therapy research (84 papers). John H. Sampson is often cited by papers focused on Glioma Diagnosis and Treatment (164 papers), Immunotherapy and Immune Responses (118 papers) and CAR-T cell therapy research (84 papers). John H. Sampson collaborates with scholars based in United States, Germany and Italy. John H. Sampson's co-authors include Darell D. Bigner, Allan H. Friedman, David A. Reardon, Henry S. Friedman, James E. Herndon, Gary E. Archer, Duane A. Mitchell, Roger E. McLendon, Peter E. Fecci and Amy B. Heimberger and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

John H. Sampson

368 papers receiving 24.2k citations

Hit Papers

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Mul... 2003 2026 2010 2018 2007 2020 2010 2018 2003 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
    2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →
  2. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
    2020 946 citations David A. Reardon, Manmeet S. Ahluwalia et al. profile →
  3. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
    2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
  4. Recurrent Glioblastoma Treated with Recombinant Poliovirus
    2018 582 citations Annick Desjardins, James E. Herndon et al. profile →
  5. Phase II Trial of Gefitinib in Recurrent Glioblastoma
    2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →
  6. Brain immunology and immunotherapy in brain tumours
    2019 480 citations John H. Sampson, Peter E. Fecci et al. profile →
  7. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
    2015 471 citations Michael Weller, Mark R. Gilbert et al. profile →
  8. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
    2015 410 citations Duane A. Mitchell, Kristen A. Batich et al. profile →
  9. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    2017 362 citations Gordana Vlahovic, Timothy F. Cloughesy et al. profile →
  10. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
    2015 313 citations David A. Reardon, Tibor Keler et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John H. Sampson United States 84 11.7k 9.8k 7.8k 6.6k 4.4k 385 24.7k
Eric C. Holland United States 77 10.1k 0.9× 6.3k 0.6× 4.7k 0.6× 12.2k 1.8× 2.4k 0.5× 230 25.7k
Allan H. Friedman United States 75 12.2k 1.0× 5.6k 0.6× 3.3k 0.4× 7.2k 1.1× 4.8k 1.1× 345 25.7k
David A. Reardon United States 89 20.8k 1.8× 8.7k 0.9× 4.9k 0.6× 10.4k 1.6× 7.3k 1.7× 560 34.0k
Kenneth Aldape United States 90 11.2k 1.0× 6.6k 0.7× 3.3k 0.4× 13.1k 2.0× 4.8k 1.1× 369 27.8k
Mark Raffeld United States 90 5.5k 0.5× 14.1k 1.4× 7.8k 1.0× 6.6k 1.0× 2.3k 0.5× 428 27.4k
Raymond Sawaya United States 84 11.6k 1.0× 7.9k 0.8× 2.5k 0.3× 8.4k 1.3× 7.2k 1.7× 351 28.2k
Owen N. Witte United States 109 9.1k 0.8× 7.3k 0.7× 9.5k 1.2× 14.8k 2.2× 3.7k 0.9× 349 35.9k
Roger E. McLendon United States 90 18.7k 1.6× 12.9k 1.3× 5.3k 0.7× 19.5k 2.9× 5.3k 1.2× 330 42.0k
Henry S. Friedman United States 95 21.5k 1.8× 9.0k 0.9× 4.2k 0.5× 15.0k 2.3× 7.9k 1.8× 567 38.4k
Cynthia Hawkins Canada 53 12.4k 1.1× 7.7k 0.8× 1.8k 0.2× 11.9k 1.8× 3.4k 0.8× 311 26.6k

Countries citing papers authored by John H. Sampson

Since Specialization
Citations

This map shows the geographic impact of John H. Sampson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Sampson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Sampson more than expected).

Fields of papers citing papers by John H. Sampson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Sampson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Sampson. The network helps show where John H. Sampson may publish in the future.

Co-authorship network of co-authors of John H. Sampson

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Sampson. A scholar is included among the top collaborators of John H. Sampson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Sampson. John H. Sampson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hotchkiss, Kelly, Sarah Cook, Ying Zhou, et al.. (2025). IL-7–mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models. Journal of Clinical Investigation. 135(12). 1 indexed citations
2.
Rhun, Émilie Le, Sara Erridge, David A. Reardon, et al.. (2025). Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open. 8(11). e2545578–e2545578.
3.
Bagley, Stephen, Shawn Kothari, Rifaquat Rahman, et al.. (2021). Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research. 28(4). 594–602. 104 indexed citations
4.
Batich, Kristen A., Duane A. Mitchell, Patrick Healy, James E. Herndon, & John H. Sampson. (2020). Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research. 26(20). 5297–5303. 80 indexed citations
5.
Desjardins, Annick, James E. Herndon, Frances McSherry, et al.. (2019). Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. Health Science Reports. 2(4). e114–e114. 11 indexed citations
6.
Gedeon, Patrick C., Teilo Schaller, Satish K. Chitneni, et al.. (2018). A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research. 24(15). 3611–3631. 38 indexed citations
7.
Riccione, Katherine A., Li-Zhen He, Peter E. Fecci, et al.. (2018). CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. OncoImmunology. 7(12). e1502904–e1502904. 10 indexed citations
8.
Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, et al.. (2017). Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research. 23(8). 1898–1909. 242 indexed citations
9.
Li, Fang, Xinjian Liu, John H. Sampson, Darell D. Bigner, & Chuan‐Yuan Li. (2016). Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. Cancer Research. 76(17). 5143–5150. 28 indexed citations
10.
Pham, Christina, Catherine Flores, Changlin Yang, et al.. (2015). Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research. 22(3). 582–595. 87 indexed citations
11.
Nair, Smita K., Gabriel De Leon, David Boczkowski, et al.. (2014). Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research. 20(10). 2684–2694. 74 indexed citations
12.
Sampson, John H., Bryan D. Choi, Luis Sánchez-Pérez, et al.. (2013). EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research. 20(4). 972–984. 241 indexed citations
13.
Vredenburgh, James J., Annick Desjardins, David A. Reardon, et al.. (2011). The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research. 17(12). 4119–4124. 112 indexed citations
14.
Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →
15.
Sampson, John H., Gary E. Archer, Duane A. Mitchell, et al.. (2009). An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8(10). 2773–2779. 221 indexed citations
16.
Desjardins, Annick, David A. Reardon, James E. Herndon, et al.. (2008). Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clinical Cancer Research. 14(21). 7068–7073. 130 indexed citations
17.
Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, et al.. (2007). Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. Clinical Cancer Research. 13(7). 2158–2167. 265 indexed citations
18.
Vogelbaum, Michael A., John H. Sampson, Sandeep Kunwar, et al.. (2007). CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS. Neurosurgery. 61(5). 1031–1038. 112 indexed citations
19.
Sampson, John H., Martin Brady, Neil A. Petry, et al.. (2007). INTRACEREBRAL INFUSATE DISTRIBUTION BY CONVECTION-ENHANCED DELIVERY IN HUMANS WITH MALIGNANT GLIOMAS. Operative Neurosurgery. 60(2). 89–99. 112 indexed citations
20.
Sampson, John H. & M. M. Binns. (2006). 2 The Kennel Club and the Early History of Dog Shows and Breed Clubs. Cold Spring Harbor Monograph Archive. 44. 19–30. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric C. Holland Breakdown of academic impact, for papers by Allan H. Friedman Breakdown of academic impact, for papers by David A. Reardon Breakdown of academic impact, for papers by Kenneth Aldape Breakdown of academic impact, for papers by Mark Raffeld Breakdown of academic impact, for papers by Raymond Sawaya Breakdown of academic impact, for papers by Owen N. Witte Breakdown of academic impact, for papers by Roger E. McLendon Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Cynthia Hawkins
Rankless by CCL
2026